Marpai (MRAI) Director Vesting: 75,000 RSUs Increase Ownership
Marpai, Inc. director Shiv Sagiv reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025, increasing his beneficial ownership to 135,000 shares of Class A common stock.
Rhea-AI Filing Summary
Marpai, Inc. director Shiv Sagiv reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025, increasing his beneficial ownership to 135,000 shares of Class A common stock. The filing indicates the RSUs were granted under a plan with a nine-month vesting schedule: 25,000 RSUs vested at three months, 25,000 at six months, and 25,000 at nine months.
The Form 4 was signed on 09/15/2025 and notes the transaction was made pursuant to a plan intended to meet the Rule 10b5-1 affirmative defense. Sagiv is identified as a director. No options or derivative transactions are reported in this filing.
Positive
- Acquisition of 75,000 RSUs vested on 08/19/2025, increasing beneficial ownership to 135,000 Class A shares
- Transaction made pursuant to a Rule 10b5-1 plan, which supports defensible timing and compliance with insider trading rules
- Staged nine-month vesting schedule (25,000 at three months, 25,000 at six months, 25,000 at nine months) aligns director and shareholder interests
Negative
- None.
Insights
TL;DR: Director acquired 75,000 RSUs, raising direct ownership to 135,000 Class A shares; transaction reflects routine equity compensation vesting.
The reported transaction is a standard equity-compensation vesting event that increases the insider's direct stake. The acquisition price is $0.00 because these are vesting RSUs rather than open-market purchases, so there is no immediate cash outlay recorded. For investors, such vesting signals continued alignment of management with shareholders but is typically not a material corporate-finance event unless part of a larger pattern of insider buying or dilution.
TL;DR: Vesting of RSUs for a director is a governance-related compensation matter and was executed under a 10b5-1 plan per the filing.
The filing notes the use of a written plan intended to satisfy Rule 10b5-1 conditions, which helps mitigate insider-trading timing concerns. The nine-month staged vesting schedule is common for retention and incentive purposes. This disclosure is routine and consistent with standard governance practices for executive and director compensation.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock | 75,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The RSUs vest over a period of nine months as follows: 25,000 RSUs vested on the three month anniversary of the grant date, 25,000 RSUs vesting on the six month anniversary of the grant date and 25,000 RSUs vesting on the nine month anniversary of the grant date.
FAQ
What did Marpai (MRAI) director Shiv Sagiv report on Form 4?
Were any open-market purchases or sales reported by Shiv Sagiv in this Form 4?
Does the filing indicate the transaction followed an insider trading plan?
What is the vesting schedule for the RSUs reported by Shiv Sagiv?
When was the Form 4 signed and filed?
AI-generated analysis. How Rhea-AI works. Not financial advice.